Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: Phase I/II study with comparative biodistribution of intact and F(ab´)2 antibodies

British Journal of Cancer

Volumn 70, Issue 3, 1994, Pages 521-525

  Lane, D M ^a   Eagle, K F ^a   Begent, R H J ^a   Hope Stone, L D ^a   Green, A J ^a   Casey, J L ^a   Keep, P A ^a   Kelly, A M B ^a   Ledermann, J A ^b   Glaser, M G ^c   Hilson, A J W ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IODINE 131;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; FEMALE; HUMAN; ISOTOPE LABELING; MALE; METASTASIS; MOUSE; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHOTON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; VOMITING;

ADULT; AGED; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; FEMALE; HALF-LIFE; HUMAN; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTOXINS; IODINE RADIOISOTOPES; MALE; MIDDLE AGE; RADIOIMMUNOTHERAPY; SUPPORT, NON-U.S. GOV'T; TISSUE DISTRIBUTION;

EID: 0027958916     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1994.338     Document Type: Article

References (23)

1. ADAM, T. (1989). Radioiodination for therapy. Ann. Clin. Biochem. 26 (Part 3), 244–245.
2. AREND, W.P. & MANNIK, M. (1972). In vitro adherence of soluble immune complexes to macrophages. J. Exp. Med., 136, 514–531.
3. I31I labelled anti-Thy 1.1 monoclonal antibody. Cancer Res., 45(4), 1536–1544.
4. BEGENT, R.H.J. & PEDLEY, B. (1990). Antibody targeted therapy in cancer: comparison of murine and clinical studies. Cancer Treat. Rev., 17(2-3), 373–378.
5. BIGLER, R.E., ZANZONICO, P.B., LEONARD, R., COSMA, M., PRIMUS, F.J., ALGER, E., DEJAGER, R., STOWE, S., FORD, E., BRENNAN, K. & GOLDENBERG, D.M. (1986). Bone marrow dosimetry for monoclonal antibody therapy. Fourth international radiopharmaceutical dosimetry symposium. Oak Ridge, Conference 85113 (DE86010102), Schlafke Stelson, A.T. & Watson. E.E. (eds). National Technology Information Service: Springfield. VA.
6. BOXER, G.M., BEGENT, R.H.J., KELLY, A.M.B., SOUTHALL, P.J., BLAIR, S.B., THEODOROU, N.A., DAWSON, P.M. & LEDERMANN, J.A. (1992). Factors influencing variability of localisation of antibodies to carcinoembryonic antigen (CEA) in patients with colorectal cancer - implications for radioimmunotherapy. Br. J. Cancer, 65(6), 825–831.
7. 131 labelled MAb F(ab’); fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. J. Nucl. Med., 31(6), 1035–1044.
8. FOWLER, J.F. (1990). Radiobiological aspects of low dose rates in radioimmunotherapy. Int. J. Radiol. Oncol. Biol. Phvs., 18(5). 1261–1269.
9. 1311 distribution by gamma camera imaging. Eur. J. Nucl. Med., 16, 361–365.
10. HARWOOD, P.J., BRITTON, D.W., SOUTHALL, P.J., BOXER, G.M., RAWLINS, G. & ROGERS, G.T. (1986). Mapping epitope characteristics on carcinoembryonic antigen. Br. J. Cancer, 54(1), 75–82.
11. 13I) anti-Bl (anti-CD20) antibody. N. Engl. J. Med., 329(7), 459–465.
12. 2 fragments from mouse IgG of various subclasses. J. Immunol. Methods, 56(2), 235–243.
13. LEDERMANN, J.A., BEGENT, R.H.J., BAGSHAWE, K.D., RIGGS, S.J., SEARLE, F., GLASER, M.G., GREEN, A.J. & DALE, R.G. (1988). Repeated antitumour therapy in man with suppression of the host response by cyclosporin A. Br. J. Cancer, 58(5), 654–657.
14. LEDERMANN, J.A., BEGENT, R.H.J., MASSOF, C., KELLY, A.M.B., ADAM, T. & BAGSHAWE, K.D. (1991). A phase I study of repeated therapy with radiolabelled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin A to suppress the immune response. Int. J. Cancer. 47(5), 659–664.
15. MIRD (MEDICAL INTERNAL RADIATION DOSE) (1975). Pamphlet No. 11, Committee of the Society of Nuclear Medicine: USA.
16. OPERATION MANUAL FOR CONTROL OF PRODUCTION. PRE- CLINICAL TOXICOLOGY AND PHASE I TRIALS OF ANTITUMOUR ANTIBODIES AND DRUG ANTIBODY CONJUGATES (1986). Br. J. Cancer, 54, 577–578.
17. PEDLEY, R.B., BODEN, J.A., KEEP, P.A., HARWOOD, P.J., GREEN, A.J. & ROGERS, G.T. (1987). Relationship between tumour size and uptake of radiolabelled anti-CEA in a colon tumour xenograft. Eur. J. Nucl. Med., 13(4), 197–202.
18. 131labelled anti-CEA antibodies in a human colonic xenograft model. Int. J. Cancer, 47(4), 597–602.
19. 131I anti-CEA antibody in a colonic xenograft model. Br. J. Cancer, 68(1), 69–73.
20. PRESS, O.W., EARLY, J.F., APPELBAUM, F.R., MARTIN, P.J., BADGER, D.C., FISHER, L.D. & BERNSTEIN, I.D. (1993). Radio- labelled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med., 329(17), 1219–1224.
21. 2 fragment in spheroids (abstract). Br. J. Cancer, 65, P 142.
22. SUTHERLAND, R, BUCHEGGER, F., SCHREYER, M., VACCA, A. & MACH, J.P. (1987). Penetration and binding of radiolabelled anti- carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular tumour spheroids. Cancer Res., 47(6), 1627–1633.
23. YOKOTA, T., MILENIC, D.E., WHITLOW, M. & SCHLOM, J. (1992). Rapid tumour penetration of a single chain Fv and comparison with other immunoglobulin forms. Cancer Res., 52(12), 3402–3408.